No widely available hantavirus vaccine exists as of mid-2026, with most candidates still in preclinical or early Phase 1 stages focused on neutralizing antibody responses to glycoproteins like Gn/Gc. mRNA platforms from Moderna and Korea University, plus DNA and viral-vector approaches, have shown protection in rodent models but require years of human trials, regulatory review, and manufacturing scale-up before potential approval. Recent 2026 outbreaks have prompted modest funding increases yet lack the priority or resources for accelerated timelines comparable to Operation Warp Speed. A realistic challenge would require unexpected Phase 3 success and emergency authorization by year-end, though current evidence indicates such rapid progress remains improbable.